A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group. [electronic resource]
Producer: 19981016Description: 1449-60 p. digitalISSN:- 0008-543X
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Blood Cell Count
- Blood Transfusion
- Carboplatin -- administration & dosage
- Child
- Child, Preschool
- Cytokines -- blood
- Drug Tolerance
- Etoposide -- administration & dosage
- Granulocyte-Macrophage Colony-Stimulating Factor -- administration & dosage
- Hematopoietic Stem Cells -- cytology
- Humans
- Ifosfamide -- administration & dosage
- Infant
- Interleukin-3 -- administration & dosage
- Length of Stay
- Neoplasm Recurrence, Local
- Neoplasms -- therapy
- Recombinant Fusion Proteins -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.